Wilmer Cutler Pickering Hale and Dorr advised Georgiamune Inc. on the transaction. Georgiamune Inc. announced the clearance of its Investigational New Drug application by the US Food...
Georgiamune’s $75 Million Series A Financing Round
Volastra Therapeutics’ $60M Series A Financing
WilmerHale represented Volastra Therapeutics on the deal. Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), closed its $60 million Series...
Verve Therapeutics’ $306 Million IPO
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
Ikena Oncology’s $143.8 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer...